LinkedIn Profile

Access KPI Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:kpitherapeutics 7596008 Feb 17th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 17th, 2018 02:25PM Feb 17th, 2018 02:25PM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 16th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 16th, 2017 08:15AM Feb 16th, 2017 08:15AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 15th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 15th, 2017 10:07AM Feb 15th, 2017 10:07AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 14th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 14th, 2017 01:50PM Feb 14th, 2017 01:50PM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 13th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 13th, 2017 04:11PM Feb 13th, 2017 04:11PM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 12th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 12th, 2017 04:15AM Feb 12th, 2017 04:15AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 11th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 11th, 2017 05:35AM Feb 11th, 2017 05:35AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 10th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 10th, 2017 06:43AM Feb 10th, 2017 06:43AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 9th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 9th, 2017 08:57AM Feb 9th, 2017 08:57AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics
private:kpitherapeutics 7596008 Feb 8th, 2018 12:00AM KPI Therapeutics 111 6.00 Open Biotechnology Feb 8th, 2017 11:57AM Feb 8th, 2017 11:57AM KPI Therapeutics is focused on developing potentially game changing autoimmune therapies. Our platform targets autoimmune diseases of the skin that have tens of millions of sufferers in the US and are a multi-billion-dollar market. Our lead drug, dalazatide, has completed Phase 1 trials and demonstrated clinical activity in patients. In diseases such as lupus, myositis, and atopic dermatitis: KPI is tackling the largest issue - a lack of effective drugs with minimal side effects. KPI’s next-generation drugs are more targeted and immune sparing than current treatments. KPI will pursue licensing opportunities with potential partners as part of its strategy. Continued achievement of clinical milestones will significantly increase KPI’s valuation, and drive liquidity and funding through the public markets. KPI’s experienced management team is focused on partnering and clinical to create a significant return on investment for investors and access to 21st century medicines for patients. A Major Opportunity in Autoimmune Diseases, especially those involving the skin More than 15 million people in the US and another 25 million in Europe and Japan have autoimmune diseases of the skin. The market opportunity for these patients’ treatments exceeds $10 billion and continues to grow each year. This includes predominantly skin-related diseases such as psoriasis and atopic dermatitis (eczema) as well as diseases with major skin manifestations such as lupus and myositis. The treatment options for many of these diseases are very limited. Patients suffering from these autoimmune diseases often rely on 60-year-old drugs with significant undesirable side effects. Even the most recently developed drugs are indiscriminate immune suppressants and have the potential to open patients up for infections and cancer. KPI Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.